Molecular Epidemiology of Cancer Research in a Nutshell Image Dr Jonine Figueroa - Principal Investigator, Chancellor’s Fellow Increasing advances of high-throughput genomic technologies are allowing better interrogation of the molecular basis of cancer. Through my affiliations with the CRUK Edinburgh Centre and the Usher Institute of Population Health Sciences and Informatics, my research program aims to clarify the interplay of genes and the environment leading to cancer, with the goal of identifying susceptible populations, with particular emphasis on breast and bladder cancer. Using detailed analyses in case-control, cohort and large consortium epidemiology studies across the globe, I have illustrated the value of integrating genetic, environmental and lifestyle factors, with benign and tumour marker data, to gain insights into cancer aetiology (e.g. Figueroa et al., JNCI 2014 and 2016). Having recently moved to UK, I aim to apply my expertise in molecular epidemiology to the unique and well curated population-based electronic medical records data in Scotland, and develop high-dimensional omics datasets, including imaging and biological specimen data, to further our understanding of the molecular mechanisms of disease, to better prevent, diagnose and treat cancer in the UK and worldwide.PeopleJonine FigueroaPrincipal Investigator, Chancellor’s FellowContactjonine.figueroa@ed.ac.uk Jonine Figueroa - Research Information CollaborationsProfessor Mark Arends, University of EdinburghProfessor David Cameron, University of EdinburghProfessor Sheila Bird, MRC Biostatistics Unit, CambridgeProfessor Douglas Easton, University of CambridgeProfessor Andrew Evans, University of DundeeGretchen Gierach, National Cancer Institute, USAProfessor Per Hall, Karolinska InstituteNick Polydorides, University of EdinburghAndy Sims, University of EdinburghSarah Vinnicombe, University of DundeePartners and FundersCarnegie Trust for the Universities of ScotlandMRC Proximity to Discovery FundWellcome Trust Seed AwardScientific Themesgenetic epidemiology, biomarkers, breast cancer, molecular pathology, bladder cancer, imaging This article was published on 2024-09-23